Q1 Earnings Forecast for Biogen Issued By Leerink Partnrs

Biogen Inc. (NASDAQ:BIIB - Free Report) - Research analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for Biogen in a note issued to investors on Wednesday, February 12th. Leerink Partnrs analyst M. Goodman forecasts that the biotechnology company will post earnings of $3.84 per share for the quarter. The consensus estimate for Biogen's current full-year earnings is $16.42 per share. Leerink Partnrs also issued estimates for Biogen's Q2 2025 earnings at $4.10 EPS, Q3 2025 earnings at $3.90 EPS, Q4 2025 earnings at $4.01 EPS, FY2025 earnings at $15.85 EPS, FY2026 earnings at $16.45 EPS, FY2027 earnings at $16.40 EPS, FY2028 earnings at $17.65 EPS and FY2029 earnings at $19.50 EPS.

Several other equities analysts have also commented on the stock. Canaccord Genuity Group dropped their price target on shares of Biogen from $298.00 to $265.00 and set a "buy" rating for the company in a research report on Thursday, February 13th. Robert W. Baird upped their price target on shares of Biogen from $294.00 to $300.00 and gave the stock an "outperform" rating in a research report on Friday, November 15th. William Blair reiterated an "outperform" rating on shares of Biogen in a research note on Monday, January 13th. TD Cowen decreased their price objective on shares of Biogen from $300.00 to $275.00 and set a "buy" rating for the company in a research note on Thursday, October 31st. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Biogen in a research note on Thursday, February 13th. Seventeen equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. Based on data from MarketBeat.com, Biogen currently has an average rating of "Hold" and a consensus target price of $211.85.

Biogen Trading Down 0.6 %

BIIB stock traded down $0.76 on Friday, hitting $136.57. 1,327,009 shares of the company were exchanged, compared to its average volume of 1,414,183. Biogen has a twelve month low of $128.51 and a twelve month high of $238.00. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.26 and a quick ratio of 0.80. The business's fifty day moving average is $146.52 and its two-hundred day moving average is $172.19. The stock has a market capitalization of $19.90 billion, a price-to-earnings ratio of 12.34, a price-to-earnings-growth ratio of 1.65 and a beta of -0.08.

Biogen (NASDAQ:BIIB - Get Free Report) last posted its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share for the quarter, beating analysts' consensus estimates of $3.43 by $0.01. Biogen had a net margin of 16.81% and a return on equity of 14.98%.

Institutional Trading of Biogen

A number of institutional investors and hedge funds have recently modified their holdings of BIIB. Larson Financial Group LLC raised its holdings in shares of Biogen by 640.9% during the fourth quarter. Larson Financial Group LLC now owns 163 shares of the biotechnology company's stock worth $25,000 after purchasing an additional 141 shares during the period. Lee Danner & Bass Inc. acquired a new stake in shares of Biogen during the fourth quarter worth $25,000. Colonial Trust Co SC raised its holdings in shares of Biogen by 9,300.0% during the fourth quarter. Colonial Trust Co SC now owns 188 shares of the biotechnology company's stock worth $29,000 after purchasing an additional 186 shares during the period. OFI Invest Asset Management acquired a new stake in shares of Biogen during the fourth quarter worth $32,000. Finally, Ashton Thomas Securities LLC acquired a new stake in shares of Biogen during the third quarter worth $33,000. 87.93% of the stock is owned by institutional investors and hedge funds.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.